NASDAQ:MACK

Delisted

Merrimack Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy MACK

*Your capital is at risk

$15.13

+0 (+0%)

At Close: Aug 19, 2024

UPDATE: Merrimack Special Dividend $1.50/Share

12:00am, Thursday, 25'th Jul 2019

Merrimack Pharmaceuticals Named New Long Idea At Seven Corners Capital, Firm Sets $10.50 Price Target And Sees 84% Upside; Calls Stock ' Relatively Safe Pharma Play with Significant Upside'

12:00am, Tuesday, 16'th Jul 2019

Merrimack Pharmaceuticals President, CEO And Director Richard Peters Resigned From Each Position As Of June 28, 2019

12:00am, Monday, 01'st Jul 2019

Merrimack Pharma 8-K Shows Amendment For Asset Purchase Deal To Extend Closing Date For Transaction From Jun. 24, 2019 To Jun. 28, 2019

12:00am, Monday, 24'th Jun 2019

The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

12:00am, Friday, 31'st May 2019

Merrimack Pharma To Issue Near-Term Special Dividend Between $16.9M-$18.9M If Asset Sale To 14ner Oncology Closes, Between $13.4M-$15.4M If Asset Sale Does Not Successfully Close

12:00am, Thursday, 30'th May 2019

Merrimack Pharmaceuticals Q1 EPS $(0.78) Up From $(1.33) YoY

12:00am, Friday, 10'th May 2019

Merrimack Pharma 8-K Shows Co. Board Committed To Implement Reduction In Headcount Affecting 13 Employees For Clinical Organization Following Discontinuation Of MM-310 Development

12:00am, Tuesday, 30'th Apr 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack ...

12:00am, Friday, 12'th Apr 2019

54 Biggest Movers From Friday

12:00am, Monday, 08'th Apr 2019

Merrimack Pharmaceuticals shares are trading higher after the company discontinued development of its MM-310 after the safety report showed Phase 1 study was unable to reach optimal therapeutic index.

12:00am, Friday, 05'th Apr 2019

Merrimack Discontinues Development Of MM-310 After Safety Update Showed Phase 1 Study Was Unable To Reach Optimal Therapeutic Index; Co. Plans To Reduce Workforce Reflective Of Narrowed Preclinical Development Pipeline

Merrimack Pharmaceuticals Stock News

UPDATE: Merrimack Special Dividend $1.50/Share

Merrimack Pharmaceuticals Named New Long Idea At Seven Corners Capital, Firm Sets $10.50 Price Target And Sees 84% Upside; Calls Stock ' Relatively Safe Pharma Play with Significant Upside'

Merrimack Pharmaceuticals President, CEO And Director Richard Peters Resigned From Each Position As Of June 28, 2019

Merrimack Pharma 8-K Shows Amendment For Asset Purchase Deal To Extend Closing Date For Transaction From Jun. 24, 2019 To Jun. 28, 2019

The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Merrimack Pharma To Issue Near-Term Special Dividend Between $16.9M-$18.9M If Asset Sale To 14ner Oncology Closes, Between $13.4M-$15.4M If Asset Sale Does Not Successfully Close

Merrimack Pharmaceuticals Q1 EPS $(0.78) Up From $(1.33) YoY

Merrimack Pharma 8-K Shows Co. Board Committed To Implement Reduction In Headcount Affecting 13 Employees For Clinical Organization Following Discontinuation Of MM-310 Development

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack ...

54 Biggest Movers From Friday

Merrimack Pharmaceuticals shares are trading higher after the company discontinued development of its MM-310 after the safety report showed Phase 1 study was unable to reach optimal therapeutic index.

Merrimack Discontinues Development Of MM-310 After Safety Update Showed Phase 1 Study Was Unable To Reach Optimal Therapeutic Index; Co. Plans To Reduce Workforce Reflective Of Narrowed Preclinical Development Pipeline

Merrimack Pharmaceuticals reports FY results

MacroGenics - Missing Data Is Rarely Good

Merrimack (MACK) Down 7.5% Since Last Earnings Report: Can It Rebound?

Top Fintech Company